Novo Nordisk Governance Shakeup Sparks Investor Concerns

Novo Nordisk DK0062498333

A dramatic boardroom overhaul at pharmaceutical giant Novo Nordisk has cemented the controlling foundation’s authority, triggering apprehension among minority shareholders about corporate governance standards. During an extraordinary general meeting, investors overwhelmingly approved a radical restructuring of the supervisory board that consolidates power with the Novo Nordisk Foundation.

Lars Rebien Sørensen, previously chairman of the foundation, now assumes the dual role of supervisory board chairman for the pharmaceutical company—an unprecedented concentration of influence in the corporation’s history. This development follows the unexpected October departures of former board chair Helge Lund and several independent members, who cited irreconcilable differences with the foundation regarding governance practices and strategic direction.